Reaction details (17:38)
- Co. shares are unmoved in reaction to the news; trades USD 6.00 (+14.07%) last.
Analysis details (17:58)
- Earlier today, the Co. announced their drug Plecanatide met the primary and secondary endpoints of a Phase IIb/III clinical study, hence company shares seen trading up over 14% last.
02 Jan 2013 - 17:36 - Equities - Source: Newswires
RANsquawk provides audio news and commentary for over 15,000 professional traders and brokers worldwide. Services include: